Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Short-Term Debt issuancesShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Leases (2016 - 2025)

Historic Leases for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $50.6 million.

  • Myriad Genetics' Leases fell 1184.67% to $50.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.6 million, marking a year-over-year decrease of 1184.67%. This contributed to the annual value of $55.0 million for FY2024, which is 1071.43% down from last year.
  • Per Myriad Genetics' latest filing, its Leases stood at $50.6 million for Q3 2025, which was down 1184.67% from $51.2 million recorded in Q2 2025.
  • Myriad Genetics' Leases' 5-year high stood at $110.6 million during Q3 2022, with a 5-year trough of $5.9 million in Q1 2023.
  • For the 5-year period, Myriad Genetics' Leases averaged around $60.1 million, with its median value being $58.9 million (2021).
  • Its Leases has fluctuated over the past 5 years, first tumbled by 9466.55% in 2023, then skyrocketed by 89830.51% in 2024.
  • Over the past 5 years, Myriad Genetics' Leases (Quarter) stood at $81.8 million in 2021, then rose by 27.02% to $103.9 million in 2022, then tumbled by 40.71% to $61.6 million in 2023, then fell by 10.71% to $55.0 million in 2024, then fell by 8.0% to $50.6 million in 2025.
  • Its Leases stands at $50.6 million for Q3 2025, versus $51.2 million for Q2 2025 and $53.4 million for Q1 2025.